IRAK-4: a new drug target in inflammation, sepsis, and autoimmunity.
Department of Biochemistry, Trinity College, Dublin 2, Ireland. wietec@tcd.ie
Claudia
C
Wietek
Luke A
LA
O'Neill
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D007113:Immunity, Innate / Q000502:physiology; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism*; D053592:Interleukin-1 Receptor-Associated Kinases / Q000378:metabolism*; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D018805:Sepsis / Q000188:drug therapy / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology
D047908:Intracellular Signaling Peptides and Proteins; C410602:TOLLIP protein, human; D053592:Interleukin-1 Receptor-Associated Kinases